Amarin Corp Plc (AMRN)

[Number sleven]

Tm100, I can't tell you what other people see. I am actually amazed that most people are able to dress and feed themselves. The Nevada judge did more damage than she could have possibly understood. By allowing generic competition into the US market when she did, she prevented that market from being built. Generic companies will not invest in building the market, and Amarin won't/can't. If you look at the weekly numbers provided by raf, and graphed by captain, you can see that the market stopped growing with the entry of the first generic. I think Amarin is doing the right thing by focusing on European markets at the moment. They need revenue from EU markets to deal with the generic competition in the US.( My opinion) What will future revenue and profits be in the EU? I can't guess. Vazkepa is currently the only Statin adjunct therapy that offers such a high residual risk reduction. I think it's well worth our investment over time.(My opinion)
Sleven,